Eulogy for the metabolic clinical investigator?

Diabetes

Volumn 65, Issue 10, 2016, Pages 2821-2823

  Vella, Adrian ^a   Jensen, Michael D ^a   Nair, K Sreekumaran ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON; GLUCOSE; INCRETIN; METFORMIN;

BODY COMPOSITION; CARDIAC MUSCLE; CLINICAL RESEARCH; DIABETES MELLITUS; EDITORIAL; FUNDING; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTRAPERITONEAL FAT; ISCHEMIC HEART DISEASE; METABOLISM; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OMENTECTOMY; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TISSUE CULTURE; ANIMAL; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PERSONNEL; UNITED STATES;

ANIMALS; BIOMEDICAL RESEARCH; DIABETES MELLITUS; HUMANS; RESEARCH PERSONNEL; UNITED STATES;

EID: 84989158706     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0923     Document Type: Editorial

References (19)

1. Nathan DG, Nathan DM. Eulogy for the clinical research center. J Clin Invest 2016;126:2388-2391
2. Himsworth HP. The activation of insulin. Lancet 1932;220:935-936
3. Himsworth HP. Diabetes mellitus: Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936;227:127-130
4. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-21
5. Holst JJ, Orskov C. Incretin hormones-an update. Scand J Clin Lab Invest Suppl 2001;234:75-85
6. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20: 876-913
7. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
8. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-260
9. Konopka AR, Esponda RR, Robinson MM, et al. Hyperglucagonemia mitigates the effect of metformin on glucose production in prediabetes. Cell Reports 2016;15:1394-1400
10. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle.8.Effects of fatty acids, ketone bodies and pyruvate, and of alloxandiabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964;93:652-665
11. Randle PJ, Priestman DA, Mistry S, Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 1994;37(Suppl. 2): S155-S161
12. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999;84(1A):3J-10J
13. Klein S. The case of visceral fat: Argument for the defense. J Clin Invest 2004;113:1530-1532
14. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010;139:448-455
15. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-1588
16. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013;12:581-594
17. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nat Rev Drug Discov 2014;13:419-431
18. Phillips B, Trucco M, Giannoukakis N. Current state of type 1 diabetes immunotherapy: Incremental advances, huge leaps, or more of the same? Clin Dev Immunol 2011;2011:432016
19. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: Objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104